Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGE family member D4 (MAGE-D4)
- Target
- MAGE-D4
- Molecular classification
- Cancer-testis antigen, MAGE (melanoma antigen) superfamily protein, Other (transcription regulation-associated protein)
01
Overview
MAGE family member D4 (MAGE-D4) is a cancer-testis antigen and a member of the MAGE (melanoma antigen gene) superfamily, which comprises proteins with restricted normal tissue expression (primarily testicular/placental) but frequent reactivation in various cancers[2][3][4][5]. MAGE-D4 is a nuclear protein involved in the negative regulation of transcription[3]. As with other MAGE proteins, it may act as a regulator of E3 ubiquitin ligase activity, modulating the stability of target proteins and influencing processes such as cell proliferation, differentiation, and apoptosis[2]. MAGE-D4 is aberrantly expressed in several tumor types and has been identified as a marker of poor prognosis and a potential therapeutic target, especially in solid tumors such as breast cancer[4]. Like other MAGE antigens, MAGE-D4 is under investigation as a diagnostic/prognostic biomarker and potential target for immunotherapy, reflecting its value as a cancer-testis antigen. No specific drugs currently target MAGE-D4, but immunotherapy approaches directed against MAGE family proteins, in general, are an active field of research[2][4].
- Other names
- MAGE-D4MAGE family member D4MAGED4
02
Mechanism of action
null (No approved or well-characterized drugs or biologics with defined mechanisms of action targeting MAGE-D4 specifically)
03
Biological functions
Negative regulation of transcription[3]Involvement in cell proliferation and differentiation processes typical of MAGE family members[1][2]Possible roles in apoptosis, cell cycle, and tumor biology as inferred from MAGE gene family properties[1][2]
04
Disease associations
Cancer (notably identified as a biomarker and therapeutic target in various tumors, including breast cancer)[4]Other (potential in germ cell development and stem cell differentiation, extrapolated from MAGE family functions)[2]
05
Safety considerations
Potential immunogenicity/toxicity if targeted with immunotherapy, as with other cancer-testis antigens[2]Risk of on-target/off-tumor effects if expression extends beyond tumors to normal tissues (requires validation for MAGE-D4 specifically)
06
Interacting drugs
null (No drugs directly targeting MAGE-D4 identified in accessible literature as of 2024; related MAGE antigens are the subject of immunotherapy research, but no direct listings are available for MAGE-D4[4])
07
Biomarkers
Marker for poor prognosis in certain cancers, e.g., breast cancer[4]Cancer-testis antigen role useful as a biomarker for cancer diagnostics and monitoring[2][5]
Beyond the preview
Go deeper on MAGE family member D4 (MAGE-D4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE family member D4 (MAGE-D4).